stockrow
Friday 6 November 2026
Export FRNM’s income statement to Excel — free account
Freenome, Inc
FRNM Healthcare Diagnostics & Research
- EPS
- −115.2%
- Free cash flow
- +12.1%
Quarter to June 2026, against a year earlier
10.47
0.83
−7.35%
Follow FRNM
Alert me
Freenome, Inc (FRNM) P/E ratio
Freenome, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 260× (June 2026) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 260×
Ten-year median
10.1×
Current reading's percentile
20
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| FRNM Freenome, Inc | n/m |
| PSNL Personalis, Inc. compare | n/m |
| VCYT Veracyte, Inc. compare | 15.2× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)